Evaluation of dyskerin expression and the Cajal body protein WRAP53β as potential prognostic markers for patients with primary vaginal carcinoma

Oncol Lett. 2022 Jan;23(1):30. doi: 10.3892/ol.2021.13148. Epub 2021 Nov 23.

Abstract

Primary vaginal cancer (PVC) is a rare gynaecological malignancy, which, at present, lacks appropriate biomarkers for prognosis. The proteins dyskerin and WD repeat containing antisense to TP53 (WRAP53β), both of which exert their functions in the telomerase holoenzyme complex, have been shown to be upregulated in different cancer types. These proteins have also been proposed as prognostic markers in some types of cancer. The aim of the present study was to examine the expression patterns of dyskerin and WRAP53β in patients with PVC. Moreover, as part of a search for effective biomarkers to evaluate prognosis in PVC, the expression of these two proteins and their potential association with clinical variables and survival were also evaluated. The expression of dyskerin and WRAP53β was assessed in PVC tumour samples from 68 patients using immunohistochemistry. The majority of tumour samples showed low and moderate expression levels of dyskerin. Upregulation of dyskerin in tumour samples was significantly associated with a shorter survival time and a poorer cancer-specific survival rate. WRAP53β was also expressed in most of the cells but was not significantly associated with clinical variables or survival. This study demonstrates that upregulation of dyskerin is significantly associated with poor prognosis. Thus, dyskerin may serve as a promising prognostic marker and a potential putative therapeutic target in PVC.

Keywords: Cajal body; WRAP53β; biomarker; dyskerin; primary vaginal carcinoma; prognosis; survival.

Grants and funding

This study was supported by The Swedish Cancer Foundation (grant nos. 110544 and CAN2011/471), The Karolinska Institute Cancer Strategic Grants (grant no. 5888-05722), The Swedish Research Council (521-2008-2899), The Stockholm County Council (grant nos. 20130097 and 20160155), The Gustaf V Jubilee Fund (grant nos. 154022 and 151202) and The Centre of Clinical Research, Västmanland County Council (grant no. LTV-940144). The funding bodies had no role in the design of the study, the collection, analysis, or interpretation of data, or in the manuscript writing.